IP Library Granted Patent US 8,124,781
Granted Patent B2
US 8,124,781 · App. 12/327,915 · Granted Feb 28, 2012

Processes for producing cycloalkylcarboxamido-pyridine benzoic acids

Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,781
App. No.
12/327,915
Granted
Feb 28, 2012
Kind
B2
Abstract

The present invention relates to a process of providing the 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in substantially free form (Compound 1).

Claims (49)

1. A process for preparing Compound 1:

comprising the steps of:

i) providing 2-bromo-3-methylpyridine (compound 2) and 3-(t-butoxycarbonyl)phenylboronic acid (compound 3),

ii) cross coupling compound 2 and compound 3 in a biphasic mixture comprising water, a first organic solvent, a first base, and a transition metal catalyst to produce compound 4,

iii) oxidizing compound 4 to produce compound 5,

iv) adding an amine group to the 6 position of the pyridyl moiety to produce compound 6,

v) reacting compound 6 with compound 7,

in a second organic solvent in the presence of a second base to produce compound 8,

vi) de-esterifying compound 8 in a biphasic mixture comprising water, a third organic solvent, and a first acid to produce compound 9,

vii) slurrying or dissolving compound 9 in a solvent for an effective amount of time to produce Compound 1.

2. The process of claim 1 , wherein the first organic solvent is an aprotic solvent.

3. The process of claim 1 , wherein the first organic solvent is toluene.

4. The process of claim 1 , wherein the first organic solvent is a protic solvent.

5. The process of claim 1 , wherein the first organic solvent is selected from methanol, ethanol, or isopropanol.

6. The process of claim 1 , wherein the first base is an inorganic base.

7. The process of claim 1 , wherein the first base is potassium carbonate.

8. The process of claim 1 , wherein the transition-metal catalyst is a palladium-based catalyst.

9. The process of claim 1 , wherein the palladium-based catalyst is Pd(dppf)Cl 2 .

10. The process of claim 1 , wherein the cross coupling reaction is run at between 60° C. and 100° C.

11. The process of claim 1 , wherein the oxidation reaction is carried out using a peroxide.

12. The process of claim 1 , wherein the oxidation reaction is carried out using peracetic acid.

13. The process of claim 1 , wherein the oxidation reaction is carried out in the presence of an anhydride.

14. The process of claim 1 , wherein the oxidation reaction is carried out in the presence of phthalic anhydride.

15. The process of claim 1 , wherein the oxidation reaction is run at between 25° C. and 65° C.

16. The process of claim 1 , wherein the amination reaction is carried out in the presence of a sulfonyl compound.

17. The process of claim 1 , wherein the amination reaction is carried out in the presence of methanesulfonic anhydride.

18. The process of claim 1 , wherein the amination reagent used in the amination reaction is an alcohol amine.

19. The process of claim 1 , wherein the amination reagent used in the amination reaction is ethanolamine.

20. The process of claim 1 , wherein the second organic solvent is an aprotic solvent.

21. The process of claim 1 , wherein the second organic solvent is toluene.

22. The process of claim 1 , wherein the second base is an organic base.

23. The process of claim 1 , wherein the second base is triethylamine.

24. The process of claim 1 , wherein the reaction between compound 6 and compound 7 is carried out in the presence of a catalytic amine.

25. The process of claim 1 , wherein the reaction between compound 6 and compound 7 is carried out in the presence of a catalytic amount of dimethylaminopyridine.

26. The process of claim 1 , wherein the third organic solvent is an aprotic solvent.

27. The process of claim 1 , wherein the third organic solvent is acetonitrile.

28. The process of claim 1 , wherein the first acid is an inorganic acid.

29. The process of claim 1 , wherein the first acid is hydrochloric acid.

30. The process of claim 1 , wherein the de-esterification reaction is run at between 20° C. and 60° C.

31. The process of claim 1 , wherein the solvent of step vii) is selected from water or a 50% methanol/water mixture.

32. The process of claim 1 , wherein the solvent of step vii) is water.

33. The process of claim 1 , wherein the effective amount of time is between 2 and 24 hours.

34. The process of claim 1 , further comprising the step of filtering the slurry of Compound 1 or concentrating the solution of Compound 1 to effect recrystallization and filtering the recrystallized Compound 1.

35. A process for preparing Compound 1 comprises the step of:

i) reacting compound 6,

with compound 7,

in a second organic solvent in the presence of a second base to produce compound 8,

ii) de-esterifying compound 8 in a biphasic mixture comprising water, a third organic solvent, and a first acid to produce compound 9,

iii) slurrying or dissolving compound 9 in a solvent for an effective amount of time to produce Compound 1.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2017
From: MILLER, MARK THOMAS; MCCARTNEY, JASON; HADIDA RUAH, SARA SABINA; ZHOU, JINGLAN
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 043203/0136 →
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 9, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037752/0752 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2008
From: SIESEL, DAVID
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 021979/0314 →
Continuity (3)
Provisional Application 61012181 · Dec 7, 2007
Provisional Application 61109573 · Oct 30, 2008
Related Publication 20090176989A1 · Jul 9, 2009